seit 2018 Deep learning for prostate cancer MRI diagnosis (Dr. Gabrani, IBM Zürich Research Laboratory, PD Dr. Patak, Klinik Hirslanden Zürich)
seit 2016 Co-Coordinator, Phase IIIb randomized trial comparing irradiation plus long-term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG (Pegasus), EORTC protocol 1414 ROG-GUCG
seit 2014 MRI-characteristics of locally advanced Prostate Cancer (Prof. Hadaschik, PD Dr. Wetter, Universität Essen)
seit 2013 Co-PI, Perioperative anti-PD-L1 antibody durvalumab (MEDI4736) in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer, SAKK 06/17
seit 2011 Movember Global Action Plan 6 (GAP6) Oligometastatic Prostate cancer, Steering committee member (Movember foundation, Australia, USA)
seit 2007 Identification of genomic determinants of tumor and metastasis heterogeneity of high risk prostate cancer and development of a lethal prostate cancer panel. (Prof. Rubin, PD Dr. Kruithof de Julio, Bern)